Chicago, Illinois--August 28,
2008--InfrAegis announced today on behalf of Bacteria Sciences Worldwide,
LLC (BSW) that DLM Capital Investors, LLC (DLM) is investing $1 billion in BSW
for 30% of the Company. DLM will receive one BSW board seat.
With respect to the press release
of InfrAegis, Inc. ("IA") issued August 25, 2008, it is very important to note
that IA's agreement with DLM Capital Investors, LLC ("DLM") has not yet
commenced.
DLM's purchase of equity in IA's
94% owned subsidiary, Bacteria Sciences Worldwide, LLC ("BSW"), is subject to
IA's prior receipt of certain funding to IA by third parties. Execution of DLM's
purchase of the equity interest in BSW is scheduled to be made in a number of
segments occurring over a period of time.
Following our August 25, 2008
press release, IA and BSW received a number of inquiries about DLM's investment
in BSW. These inquiries have essentially asked the same question: How does this
effect prior investments in IA? Upon final consummation of the DLM investment,
IA investors will continue to own the majority share of BSW, and DLM's
investment will allow BSW to execute its business plan. Future financial
arrangements for IA and BSW will be subject to IA's Board of Directors' review
of investment bankers’ recommendations.
Donn Morrow, President and CEO of DLM said, "I
really believe in BSW and its ability to deal with significant common problems
like food safety, and their harmful bacteria identification capability. I
believe BSW’s innovative products will aide in potentially protecting us from
the affects of radiation poisoning, from the affects of dirty bombs, and from
the affects of ultra-violet A, B, & C caused by the thinning of the ozone
layer". Michelle Butler, Chief Operating Officer of DLM, stated, "BSW has an
exciting future. We want to be a part of it and we want to serve mankind".
InfrAegis welcomes
"the DLM team", their financial
support, and their belief in the BSW teams’ scientists and management.
DLM, The Company of
Entrepreneurs, is a U.S. firm operating on a global scale to develop, enhance,
and support communities by creating, overseeing, and investing in projects and
programs dealing with today's most troublesome issues. DLM strives to create
jobs, provide liquidity in the US market, and develop cutting-edge solutions by
providing the necessary capital. For more information visit: www.dlm-ci.com.
BSW offers exciting
products and services that provide for food safety, improve health and promote
Human Continuity™. Please see our website at www.ia-bsw.com.
Our Molecular Microbial DNA Detection System created by Dr. Robert Levin rapidly
identifies harmful bacteria like E.coli 0157 H:7, Salmonella and others. BSW’s
Gamma Nutraceuticals™ platform created by Dr. Kalidas Shetty, seeks to protect
mankind, animals, fish, fowl, seeds, and plants from the destructive effects
from ultra-violet A, B, and C radiation poisoning that may cause skin cancers,
dysentery, and damage to the eyes. The C3 anti-microbial sanitizers hold promise
in combating MRSA, Staph, E.Coli 0157 H:7, and other harmful bacteria and
viruses. "We are very pleased with the progress that the company has made" said
Gregory E. Webb, Chairman of the Board and Chief Executive Officer.
Please visit www.ia911.com
for all the exciting
products and services provided by InfrAegis Inc. BSW has licensed certain
patents and intellectual property from InfrAegis. InfrAegis provides management
and financial services to BSW.
This announcement contains historical and forward-looking information. There are
significant risks and uncertainties about the markets that both InfrAegis and
BSW are entering. Execution of the strategies will be difficult and
unpredictable given there are no analogs to InfrAegis’ and or BSW’s products,
product platforms and services. BSW is targeting initial product delivery will
be approximately 9 to 12 months. Kits for the Molecular Microbial DNA Detection
System are available now and target delivery for modular kits will be in
approximately 4 months. Target delivery of the fully automated and integrated
solution sets is in approximately 9 months.
For Company information on InfrAegis or BSW please contact:
Marie Diffley (mdiffley@ia911.com) or Robert Langlois (rlanglois@ia911.com) at
1-847-593-0093
InfrAegis, Inc is a security technology and media distribution company that provides products, solutions, and countermeasures to protect and defend borders, ports, mass transit systems, airports, financial institution systems, and critical infrastructure against acts of terrorism. Established in 2003, InfrAegis is highly regarded for its ability to implement leading-edge technology to detect, analyze and monitor weapons of mass destruction and hazardous/contraband materials. The company is dedicated to applying predesignated countermeasures during emergency situations to save lives, protect assets, and mitigate damage. InfrAegis is based in Chicago, IL, with offices in Washington DC, and affiliated offices in Athens, Madrid, Mexico City, and Singapore.
This press release contains forward-looking statements about InfrAegis, Inc. that involve risks and uncertainties. These statements are developed by combining currently available information with InfrAegis’ beliefs and assumptions. Forward-looking statements do not guarantee future performance. Because InfrAegis cannot predict all of the risks and uncertainties that may affect it, nor control the ones it does predict, InfrAegis’ actual results may be materially different from the results expressed in its forward-looking statements.
You can learn more about InfrAegis, Inc. at www.ia911.com.
Return to index of press releases